Private blood testing has quietly become one of the most requested add-ons in UK telehealth. Patients on weight-management programmes need baseline and monitoring bloods. Men's health services can't responsibly run TRT pathways without them. Hair-loss patients want the common deficiencies ruled out before committing to treatment. Until now, most clinics and brands have solved this with a patchwork: sending patients to a third-party testing company with someone else's branding, someone else's results portal, and someone else's upsell emails landing in their patient's inbox.
That patchwork has a cost. The moment your patient buys a test from another company's website, you've handed over part of the relationship you worked to build. This is the problem white-label diagnostics exists to solve — and it's why we've launched PExpo Diagnostics, a white-label at-home blood testing platform for UK clinics and consumer health brands.
What white-label blood testing actually means
White-label testing follows the same logic as white-label telehealth: the patient-facing layer belongs to you, the operational layer belongs to the platform. In practice, that means the kit box that lands on the patient's doormat carries your logo. The instructions inside are written under your identity. The results arrive in a portal styled as your brand, with your follow-up path attached.
Behind that front, the platform runs everything operational: kit assembly and fulfilment, tracked postage in both directions, accredited UK laboratory analysis, and results delivery with reference ranges for every biomarker. The patient never meets the infrastructure provider — which is exactly the point.
One important distinction from most testing companies on the market: a genuine white-label provider doesn't compete with its own partners. PExpo Diagnostics doesn't sell kits to the public at all. If a consumer wants to buy one, they buy from a retail partner — such as Farmeci or My London Pharmacy — under that partner's own brand. Your platform provider should never be your competitor.
The panels that matter in 2026
Test menus can sprawl into hundreds of biomarkers, but demand in private testing concentrates around a handful of pathways. The launch menu for a white-label range should map to the treatment programmes UK operators actually run:
- Testosterone and TRT. A finger-prick advanced testosterone profile (total and free testosterone, SHBG, Free Androgen Index, albumin) for screening — and a venous TRT confirmatory profile for the full work-up: hormones, LH, FSH, prolactin, oestradiol, full blood count, lipids, HbA1c and PSA. Guidance from the British Society for Sexual Medicine expects confirmatory venous testing before treatment, so a credible men's health pathway needs both tiers.
- Weight-loss screening and monitoring. Pre-treatment screening (HbA1c, liver function, lipids) and ongoing monitoring panels that add iron status and B vitamins — with a Vitamin D option — matched to the check-in cadence of GLP-1 programmes.
- Hair loss. Iron profile, active B12, folate and thyroid function — the blood-level drivers a prescriber wants excluded before treating.
- Liver function and statin monitoring. Simple, high-volume panels that support ongoing prescribing safely.
A fixed menu is a starting point, not a ceiling. The operators with the strongest economics tend to be the ones who shape a panel around their own clinical pathway — which is why custom panel configuration per brand enquiry matters more than the length of the standard list.
Key takeaway: patients increasingly expect testing, treatment and follow-up to come from one name. Operators who send patients to a third-party testing brand leak both revenue and relationship. White-label testing keeps the whole loop — test, result, consultation, treatment, re-test — under your identity.
Collection methods: finger prick, upper-arm devices, and venous
Most panels run on a finger-prick sample the patient collects at home in a few minutes and posts back in a prepaid pack. It's cheap, familiar and good enough for the majority of biomarkers.
Two other methods fill the gaps. Upper-arm self-collection devices (the Tasso/Autodraw category) draw a larger sample with less discomfort — a meaningful upgrade for patients who struggle with finger-prick volumes, and a premium option brands can position accordingly. And some panels are venous by clinical necessity: a TRT confirmatory profile needs a proper draw, arranged either in clinic or through at-home phlebotomy.
The mix matters commercially as well as clinically. Finger prick keeps the entry price accessible; the venous tier supports the higher-stakes clinical decisions. Prescriber discretion applies throughout — a blood result is an input to a clinical judgement, not a substitute for one.
Who this fits: clinics vs brands
For clinics with their own clinicians, white-label testing slots in alongside dispensing. You already own the clinical relationship; branded testing means the baseline bloods, the monitoring schedule and the results conversation all stay inside your service. We covered the operational groundwork of running a testing service — phlebotomy options, acting on results, governance — in our earlier guide to adding a private blood testing service to a UK clinic.
For brands on a white-label telehealth stack, testing becomes a product line rather than an outbound referral. A weight-management brand can sell a monitoring panel as part of its programme. A men's health brand can run screen-confirm-treat-monitor as one journey on one domain. In our observation, testing also earns its keep as an acquisition product: a blood test is a lower-commitment first purchase than a treatment subscription, and it starts the relationship with data.
The test kit is the first physical thing most patients ever receive from your brand. It either builds the relationship under your name — or hands it to whoever printed their logo on the box.
What to check before you launch
A white-label testing range is operationally real — samples, cold mornings, postboxes, lab cut-offs. Before launching, satisfy yourself on the fundamentals:
- Laboratory accreditation. Ask where samples are analysed and to what standard. UK laboratories operating to UKAS-accredited standards are the benchmark for private testing.
- Sample logistics. Tracked postage both ways, sensible packaging that survives the Royal Mail network, and a clear process for insufficient or haemolysed samples that need a re-collect.
- Results presentation. Reference ranges per biomarker, clear flagging, and control over how results connect to your follow-up pathway — because a result without a next step is a support ticket.
- Clinical governance fit. Who reviews results, who contacts the patient about an urgent flag, and how out-of-range findings route into a consultation. Clinics keep this in-house; brands should expect their platform's clinical workflow to handle it.
- Custom panel capability. If your pathway needs a marker the standard menu lacks, the provider should be able to configure it — subject to lab scope and governance review — rather than force your protocol to fit their list.
None of this is glamorous, and all of it is the difference between a testing range that supports a clinical service and one that generates complaints. The good news: it's now infrastructure you can plug into rather than build.
